Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer Excellence Forum

Non-Small Cell Lung Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology
FDA Approval
10/03/2024
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center
Videos
09/17/2024
Jamie Chaft, MD, discusses the 5-year follow-up data from the IMpower010 trial which showed atezolizumab continued to provide greater improvement to disease-free survival than best supportive care for patients with resectable early-stage...
Jamie Chaft, MD, discusses the 5-year follow-up data from the IMpower010 trial which showed atezolizumab continued to provide greater improvement to disease-free survival than best supportive care for patients with resectable early-stage...
Jamie Chaft, MD, discusses the...
09/17/2024
Oncology
Sarah Smith, Virginia Cancer Specialists
Videos
05/24/2024
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses...
05/24/2024
Oncology
Nicolas Girard, MD, Institut Curie
Videos
10/23/2023
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology
Tina Cascone, MD, PhD, MD Anderson Cancer Center
Videos
10/23/2023
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses...
10/23/2023
Oncology
Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Videos
07/17/2023
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
07/17/2023
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Corey Langer, MD, Abramson Cancer Center
Videos
06/14/2023
At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...
At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...
At the 2023 Great Debates and...
06/14/2023
Oncology
Kim Norris, Lung Cancer Foundation of America
Videos
05/16/2023
At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...
At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...
At the 2023 Great Debates and...
05/16/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement